The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients
Adult
Male
China
Adolescent
T-Lymphocytes
Immunology
Antibodies, Viral
Severity of Illness Index
Young Adult
03 medical and health sciences
0302 clinical medicine
Humans
Child
SARS-CoV-2
COVID-19
antibody response
RC581-607
Middle Aged
host immune response
Immunoglobulin A
3. Good health
Immunoglobulin M
Immunoglobulin G
cytokine production
Cytokines
disease severity
Female
Immunologic diseases. Allergy
DOI:
10.3389/fimmu.2021.632814
Publication Date:
2021-03-04T05:09:16Z
AUTHORS (20)
ABSTRACT
Increasing evidence suggests that dysregulated immune responses are associated with the clinical outcome of coronavirus disease 2019 (COVID-19). Nucleocapsid protein (NP)-, spike (S)-, receptor binding domain (RBD)- specific immunoglobulin (Ig) isotypes, IgG subclasses and neutralizing antibody (NAb) were analyzed in 123 serum from 63 hospitalized patients with severe, moderate, mild or asymptomatic COVID-19. Mild to modest correlations were found between disease severity and antigen specific IgG subclasses in serum, of which IgG1 and IgG3 were negatively associated with viral load in nasopharyngeal swab. Multiple cytokines were significantly related with antigen-specific Ig isotypes and IgG subclasses, and IL-1β was positively correlated with most antibodies. Furthermore, the old patients (≥ 60 years old) had higher levels of chemokines, increased NAb activities and SARS-CoV-2 specific IgG1, and IgG3 responses and compromised T cell responses compared to the young patients (≤ 18 years old), which are related with more severe cases. Higher IgG1 and IgG3 were found in COVID-19 patients with comorbidities while biological sex had no effect on IgG subclasses. Overall, we have identified diseases severity was related to higher antibodies, of which IgG subclasses had weakly negative correlation with viral load, and cytokines were significantly associated with antibody response. Further, advancing age and comorbidities had obvious effect on IgG1 and IgG3.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (69)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....